Connection

Elizabeth Garrett-Mayer to Antineoplastic Combined Chemotherapy Protocols

This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Antineoplastic Combined Chemotherapy Protocols.
  1. Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 05; 119(1):55-63.
    View in: PubMed
    Score: 0.299
  2. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
    View in: PubMed
    Score: 0.088
  3. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012 Nov; 97(11):1736-42.
    View in: PubMed
    Score: 0.078
  4. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol. 2013 Dec; 11(4):306-15.
    View in: PubMed
    Score: 0.078
  5. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012; 82(2):67-74.
    View in: PubMed
    Score: 0.076
  6. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
    View in: PubMed
    Score: 0.074
  7. Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
    View in: PubMed
    Score: 0.073
  8. Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survival. J Med Imaging Radiat Oncol. 2010 Oct; 54(5):483-9.
    View in: PubMed
    Score: 0.069
  9. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol. 2010 Aug; 33(4):346-52.
    View in: PubMed
    Score: 0.069
  10. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
    View in: PubMed
    Score: 0.066
  11. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010 Jan 01; 16(1):203-11.
    View in: PubMed
    Score: 0.066
  12. Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer. J Clin Oncol. 2009 Jun 10; 27(17):2816-22.
    View in: PubMed
    Score: 0.063
  13. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52.
    View in: PubMed
    Score: 0.061
  14. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1108-13.
    View in: PubMed
    Score: 0.061
  15. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009 Jan; 58(1):49-59.
    View in: PubMed
    Score: 0.059
  16. Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst. 2008 May 07; 100(9):681-2; author reply 682-3.
    View in: PubMed
    Score: 0.059
  17. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007 Sep 01; 25(25):3965-70.
    View in: PubMed
    Score: 0.056
  18. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2005 Dec 01; 11(23):8413-7.
    View in: PubMed
    Score: 0.050
  19. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol. 2003 Aug 15; 171(4):2161-9.
    View in: PubMed
    Score: 0.042
  20. A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer. Breast Cancer Res Treat. 2002 Nov; 76(2):145-56.
    View in: PubMed
    Score: 0.040
  21. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.
    View in: PubMed
    Score: 0.015
  22. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007 Nov 01; 13(21):6396-403.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.